Cancer Therapy Advisor

Dr Jason Efsthathiou, presents PEACE-3 data: Adding Radium-223 to enzalutamide prolongs rPFS (19.4 vs 16.4 mo, HR 0.69) in #mCRPC with bone metastases. Research from Dr Enrique Gallardo.

Read the review and watch the full interview at: ➡️ https://bit.ly/4rNUPUK

#MedEd #OncTwitter #ProstateCancer

Dr. Scott Tyldesley of UBC reports on 15-year ASCENDE-RT data: Brachytherapy boost halves PC-specific mortality (8.6% vs 16.4%, P=.007) but shows no OS benefit.

Read more here: ➡️ https://bit.ly/3OGoIaH

#pcsm #prostatecancer #ASCOGU26 #GU26

What workouts help during and after breast cancer? After breast cancer or after menopause, women need to exercise using strength and resistance training to maintain muscle mass and health.

Learn expert tips on exercise, recovery, and feeling your best. https://bit.ly/49E3pyH

A majority of older patients with #advancedcancer have indicated they prioritize #QOL over extending survival. Published by @jamaoncology.com.

https://bit.ly/47FVkb8

#CancerCare

Childhood Cancer Incidence, Deaths Projected to Increase in Low-Income Countries Investigators assessed the global, regional, and national burden of childhood cancer.

#Childhoodcancer deaths are expected to increase nearly 45% in low-income countries while decreasing in high-income areas by 2050. Published in @americancancersoc.bsky.social CA Cancer Journal.

https://bit.ly/40WgY7c

The ORR was 28.2% for younger patients and 30.4% for older patients, and the DCR was 43.9% and 48.8%, respectively.

https://bit.ly/4smejPS

#melanoma #melsm #skcsm

National Association for Continuing Education National Association for Continuing Education online learning classes

Elevate #Oncology Patient Care and Your Career: Attend the 2026 ONA Summit on March 20-21 for free live virtual #CE led by expert faculty. Designed for oncology nurses in all roles. Register here: https://bit.ly/4qjckL5

People who live in a county close to an operational nuclear power plant have a higher rate of #cancermortality than those living farther away. Published in @natmed.nature.com.

Read more here: ➡️ https://bit.ly/40KhYv5

#CancerDeath #CancerRisk

NCCN NSCLC Guidelines Update Staging, Emphasize Molecular Testing The National Comprehensive Cancer Network's newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab deruxtecan-dlink a preferred option for some patients in se...

New NCCN Guidelines for #NSCLC emphasize integrated staging and molecular testing. Molecular analysis is mandatory for all nonsquamous NSCLC cases to guide targeted therapy.

Read the review: https://bit.ly/4b28ksw

#MedEd #OncTwitter #LungCancer #LCSM

Posterior Fossa Syndrome Linked to Long-Term Neurocognitive Deficits in Medulloblastoma Survivors Investigators evaluated the long-term neurological, neurocognitive, social, and quality of life outcomes associated with posterior fossa syndrome among survivors of medulloblastoma.

Survivors of childhood #medulloblastoma who also had a history of posterior fossa syndrome experienced long-term neurocognitive and physical impairments. Published in @jamanetworkopen.com.

https://bit.ly/4bhJxlE

#PediatricCancer

GLP1-RA Therapy May Improve OS, But Not DFS, in Breast Cancer Survivors In this retrospective analysis, researchers studied adult patients who were diagnosed with non-metastatic breast cancer and received GLP1-RAs for at least 3 months.

#GLP1-RA use may improve OS in #breastcancer survivors. Published in @aacrjournals.bsky.social journal Cancer Research Communications.

https://bit.ly/479Sg6O

#bcsm

ASCO Genitourinary Cancers Symposium Archives

Now that the ASCO Genitourinary Cancers Symposium 2026 has come to an end, check out our conference coverage all in one convenient location. @ascocancer.bsky.social #GU26 https://bit.ly/400JzIg

Antitumor Activity Seen With Fruquintinib Plus Serplulimab in Untreated, Advanced nccRCC The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.

Researchers found a 9-month progression-free survival rate with the combination of fruquintinib and serplulimab for treatment-naive advanced non-clear cell renal cell carcinoma (nccRCC). @ascocancer.bsky.social #GU26 #GUCSM https://bit.ly/46APibz

The RFS benefit of adjuvant pembrolizumab given for high-risk stage II #melanoma persists even after accounting for new melanoma diagnoses. Published in @jamanetworkopen.com.

https://bit.ly/4kUR9xH

#melcsm #skcsm

Cabazitaxel Does Not Improve Survival in Very High Risk Localized PCa Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk prostate cancer.

Adding cabazitaxel to androgen deprivation therapy and radiotherapy does not improve outcomes in very high risk localized prostate cancer, according to research presented at #GU26.

KEYMAKER-U04: Targeted ICIs do not Improve Efficacy in Advanced Urothelial Cancer Adding LAG-3 or TIGIT ICIs to enfortumab vedotin + pembrolizumab did not improve efficacy in pts with locally advanced or metastatic carcinoma

In locally advanced/metastatic urothelial cancer, adding favezelimab or vibostolimab to first-line treatment with enfortumab vedotin and pembrolizumab is not associated with response or PFS, according to research presented at #GU26. #gucsm

Durvalumab + Tremelimumab Associated With Improved DFS, Worse QoL in RCC Patients who receive durvalumab plus tremelimumab for resected RCC report worse quality of life compared to those who receive active monitoring.

Patients who receive durvalumab + tremelimumab for resected #RCC report worse QoL than patients who receive active monitoring, according to research presented at #GU26.

Gem-iDRS + Cetrelimab Does Not Improve Survival in MIBC Gemcitabine intravesical system+intravenous cetrelimab did not improve bladder-intact event-free survival or OS for pts with MIBC who did not receive radical cystectomy.

In patients with #MIBC who did not undergo radical cystectomy, treatment with gemcitabine intravesical system plus cetrelimab did not show superior efficacy over concurrent chemoradiation therapy, according to research published at #GU26.

ASH Releases Clinical Practice Guidelines for ALL in Adolescents and Young Adults In AYAs, the ASH guideline panel recommends pediatric-inspired (asparaginase-containing) regimens for treatment-naïve B-ALL and T-ALL, and blinatumomab for relapsed/refractory B-ALL.

@ash.hematology.org has released new guidelines on the treatment of adolescents and young adults with #acuteLymphoblasticLeukemia. Guidelines are available for both treatment-naïve and relapsed/refractory disease.

https://bit.ly/40tBMCP

#ALL #leusm

ASCO GU 2026: Are Combinatorial Therapies the Future Standard of Care in RCC and MIBC? Findings presented at the 2026 ASCO GU Symposium show that combinatorial therapies may provide new treatment options for patients with renal cell carcinoma or muscle-invasive bladder cancer.

Highly anticipated results presented at #GU26 show that combinatorial therapies may provide much-needed answers for #RCC and #MIBC patient populations.

Prostate Brachytherapy Boost Does Not Prolong OS in Prostate Cancer at 15 Years In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

New from ASCO Genitourinary Cancers Symposium 2026: Prostate Brachytherapy Boost Does Not Prolong OS in Prostate Cancer at 15 Years

@ascocancer.bsky.social #GU26 https://bit.ly/3OGoIaH

February is National #CancerPreventionMonth 💜
• 60.8% of U.S. women prefer in-clinic #cervicalcancer screening
• 20.4% prefer at-home self-sampling
• 18.8% remain unsure

Professional screening remains the gold standard

Read more: https://bit.ly/46pKoOo

#NationalCancerPreventionMonth #MedEd

AEs Associated with Capivasertib+Abiterone Did Not Adversely Affect HRQoL in PTEN-Deficient mHSPC Capivasertib+abiraterone was associated with more symptomatic AEs but did not impact HRQoL in patients with PTEN-deficient mHS prostate cancer.

More from ASCO GU: Capivasertib plus abiterone resulted in more AEs and faster declines in well-being scores in patients with mHS prostate cancer, but HRQoL scores were not impacted, and most patients could be managed with supportive care. @ascocancer.bsky.social #GU26 https://bit.ly/3N9tCMW

Disitamab Vedotin Has Anticancer Activity Across HER2 Expression Profiles in la/mUC Disitamab vedotin has shown antitumor activity in HER2-expressing subgroups with pretreated, locally advanced unresectable or metastatic urothelial cancer.

Disitamab vedotin has shown antitumor activity across HER2-expressing subgroups with pretreated, HER2-positive, locally advanced unresectable or metastatic urothelial cancer, according to research presented at @ascocancer.bsky.social #GU26 https://bit.ly/4r1yHVG

Stable QoL, High Treatment Adherence Seen in Real-World Use of Relugolix for Prostate Cancer Use of relugolix among prostate cancer patients is associated with QoL, high treatment adherence rates, and low rates of serious adverse events.

In a study on relugolix serious adverse events occurred in 3.9% of patients over the 6-month study period. Read more about this study presented at @ascocancer.bsky.social #GU26 here:https://bit.ly/4aDylzy

Abiraterone-Prednisone-Olaparib Improves OS in BRCA1/2- or ATM-Altered mCRPC In mCRPC patients with BRCA1/2 or ATM alterations, first-line treatment with abiraterone plus prednisone and olaparib improves OS.

First-line treatment with abiraterone plus prednisone and olaparib is associated with improved OS for those with mCRPC and BRCA1/2 or ATM alterations.

@ascocancer.bsky.social #GU26 https://www.cancertherapyadvisor.com/reports/abiraterone-prednisone-olaparib-os-brca1-2-atm-altered-mcrpc/

Adding Radium-223 to Enzalutamide Improves OS in mCRPC With Bone Metastases For patients with mCRPC with bone metastases, the addition of radium-223 to enzalutamide therapy is associated with improved overall survival.

The addition of radium-223 to enzalutamide therapy is associated with improved overall survival for those with mCRPC.

Read more about this study here. @ascocancer.bsky.social #GU26
https://www.cancertherapyadvisor.com/reports/adding-radium-223-enzalutamide-os-mcrpc-bone-metastases/

ASCO GU 2026 to Highlight the Latest Developments in Genitourinary Cancer The presentations at ASCO GU signal a move toward more personalized, potent, and sequence-specific treatment strategies for genitourinary malignancies.

Check out some of the highlights and latest developments in genitourinary cancer that'll be presented at the 2026 Genitourinary Cancers Symposium. @ascocancer.bsky.social #GU26 https://www.cancertherapyadvisor.com/reports/asco-gu-2026-to-highlight-the-latest-developments-in-genitourinary-cancer/

ASCO Genitourinary Cancers Symposium Archives

Our 2026 ASCO Genitourinary Cancers Symposium coverage is live! Check out our live coverage using the link below. @ascocancer.bsky.social #GU26 https://www.cancertherapyadvisor.com/conferences/asco-genitourinary-cancers-symposium/

• 90% of #cancersurvivors report lifestyle barriers.
• Lack of energy (51.3%) and physical limitations (48.3%) are the primary obstacles.
• Time constraints affect 27.6%.

Research from @ascopost.bsky.social, read more: ➡️ https://bit.ly/4ruVOc6

#Oncology #Survivorship #PublicHealth #PatientCare